Kenya will begin the national rollout of Lenacapavir, a long-acting HIV prevention injection, on Thursday, February 26, 2026, as part of efforts to cut new infections to zero by 2030.
Eligibility and Precautions
Health experts have clarified that not everyone at risk of contracting HIV will qualify for the jab. It will be administered only to individuals who:
- Test HIV-negative
- Have not had potential exposure to the virus within the past 72 hours
Clients are also advised to disclose any other medication they are using including sexual performance enhancement drugs and tuberculosis treatment to healthcare providers, due to possible harmful drug interactions.
HIV Burden in Kenya
Kenya recorded just over 19,000 new HIV infections in 2024, translating to about 52 new infections daily. Officials hope the rollout of Lenacapavir will accelerate progress toward the national goal of zero new infections by 2030.
Lenacapavir as a Prevention Option
Lenacapavir, a form of long-acting pre-exposure prophylaxis (PrEP), will complement existing prevention methods such as oral PrEP and Cabotegravir.
Studies show that when administered correctly, Lenacapavir is up to 96% effective in preventing HIV. Eligible clients will receive two injections per year, administered once every six months.
Three-Phase Rollout
Kenya has outlined a phased rollout strategy:
- Phase One – 15 counties with the highest HIV burden and new infection rates
- Phase Two – another 15 counties
- Phase Three – the remaining 17 counties
The rollout is expected to expand access to HIV prevention services, particularly for individuals who may struggle with daily oral medication.
Conclusion
The introduction of Lenacapavir marks a significant milestone in Kenya’s HIV prevention strategy. By combining modern medical innovation with targeted rollout, the country aims to strengthen its fight against HIV and move closer to achieving zero new infections by 2030.
